March 2026 Research Update

This month included a human trial suggesting that regular, simple physical activity may improve some metabolic and liver-related blood tests in a specific group of children with PKU. In an 8-week walking program, children who walked showed improvements while those on a waitlist did not, with changes seen in body weight measures and several liver enzymes. This adds to the picture that health issues that can occur alongside PKU, such as fatty liver disease, may be influenced by lifestyle factors that are not directly about phenylalanine levels. [1]

The study focused on children aged 9 to 12 years who had PKU, were overweight or obese, and also had non-alcoholic fatty liver disease. Compared with the waitlist group, the walking group had improvements in BMI and in blood tests often used to track liver irritation (including ALT, AST, GGT, and ALP), as well as triglycerides. The report did not describe safety problems in the summary provided, and it also did not include longer-term follow-up beyond the 8-week period. [1]

For families dealing with PKU plus concerns like excess weight or fatty liver disease, this trial adds early clinical evidence that a structured walking routine can coincide with measurable improvements in liver-related labs over a short timeframe. This does not answer whether walking changes phenylalanine control or long-term outcomes, because those details were not reported in the summary. What it clarifies now is that researchers are testing practical, non-drug approaches to common health concerns that can come along with PKU, and that these can be studied in randomized trials. [1]

Two studies this month focused on measuring PKU-related chemistry in urine, with the shared message that urine testing may capture more than just phenylalanine and could eventually support more detailed monitoring. One study moved toward a practical, at-home urine test for certain keto acids linked to PKU, while another study mapped broader urine metabolic patterns that differed across PKU-related conditions. Together, these studies point to a future where urine markers might help describe metabolic status in a more detailed way, but both approaches still need broader confirmation before they are part of routine care. [2] [3]

In laboratory development work using urine samples, researchers created a color-based test designed to measure urinary keto acids linked to PKU and related disorders, and they built a prototype kit intended for home use. Results from PKU urine samples showed strong agreement with an advanced laboratory reference method, meaning the color-based approach tracked the lab measurements closely in the samples tested. Important gaps remain, including that PKU clinical testing was limited to a small number of adult samples and some comparisons relied on spiked urine rather than real-world samples. [2]

In a pediatric urine profiling study, researchers found that children with classic PKU, BH4-responsive PKU, and milder hyperphenylalaninemia did not all share the same urine metabolic pattern. Classic PKU showed stronger signals from phenylalanine-related pathways and higher excretion of some vitamin-related compounds, while several other amino-acid-related and energy-related metabolites were reduced. The BH4-responsive group showed the most varied pattern, and the milder hyperphenylalaninemia group looked closer to healthy controls in this dataset. [3]

This body of work mainly matters as research that could shape how PKU is monitored in the future. The at-home urine test concept is promising because it aims to make measuring certain PKU-related metabolites simpler and more accessible, but it is not yet established for everyday use and was tested on limited real PKU samples. The metabolomics profiling study helps clarify that different PKU-related conditions can look different across many body chemicals, which may help explain why people can have different metabolic experiences even when they share a diagnosis, but it does not by itself tell which markers should be acted on. [2] [3]

Two reports this month highlighted that PKU can look quite different across people and across places, even when the diagnosis is the same. A nationwide newborn screening report showed PKU as a leading detected condition and noted regional and ethnic variation in inherited metabolic diseases, while a family case report showed striking differences in cognition between two untreated sisters with similar lab and genetic findings. Together, these studies reinforce that PKU is not a single uniform experience and that both biology and context may shape outcomes in ways that are still not fully explained. [4] [5]

In Russia's expanded newborn screening program over 2 years, PKU was the most frequently confirmed inherited metabolic disease in the screened newborn population. The report also described that detection patterns varied by region and ethnicity, and it highlighted the use of next-generation genetic testing to help confirm or clarify difficult cases after an initial positive screen. This type of national data helps set expectations about how often PKU is found through screening and how screening programs function at scale, including the reality of false positives and the need for confirmatory testing. [4]

In a report of two adult sisters with untreated PKU, one sister had normal cognition while the other had intellectual disability, despite very similar long-term plasma phenylalanine levels and the same PAH gene changes. Extensive testing did not identify a clear biochemical or genetic reason for the difference, and brain phenylalanine levels could not be measured. The case adds to the understanding that common measurements may not fully explain brain-related outcomes in every person with PKU, especially when looking at rare, individual situations. [5]

For patients and caregivers, these studies add context rather than changing day-to-day management. The screening report shows that large programs can find PKU reliably and that confirmatory testing, including genetic testing, is often needed after an initial positive result, which helps explain why screening is a process rather than a single test. The sister case report underscores an uncertainty that families often feel: even detailed blood tests and genetics may not fully predict cognitive outcomes for every individual, and researchers still cannot measure or explain every factor that matters for the brain. [4] [5]